Uterus mass - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Diagnose benign or malignant diseases affecting female reproductive organs

₹699₹1,500

53% OFF

Uterus Mass - Large Biopsy 3-6 cm: Comprehensive Medical Test Guide

Why is it done?
- Test Description: A tissue sampling procedure that obtains a diagnostic sample from a uterine mass measuring 3-6 cm in diameter for histopathological analysis to determine the nature and characteristics of the lesion.
- Primary Indications: Evaluation of abnormal uterine masses detected on imaging (ultrasound, MRI, or CT); differentiation between benign (fibroids, polyps) and malignant lesions; staging of endometrial or uterine carcinoma; assessment of lesions causing abnormal uterine bleeding or postmenopausal bleeding
- Clinical Circumstances: When imaging shows a mass 3-6 cm with unclear characteristics; when conservative management is being considered; prior to treatment planning; monitoring of previously identified lesions; assessment of treatment response
- Typical Timing: Usually performed within 2-4 weeks of imaging confirmation; scheduled during the follicular phase of menstrual cycle when possible; as soon as clinically feasible when malignancy is suspected
Normal Range
- Normal/Reference Findings: Benign endometrial tissue; benign leiomyoma (fibroid) tissue; benign polyp tissue; normal endometrial stroma without atypia or malignancy; absence of abnormal cells or architectural abnormalities
- Result Interpretation: Negative/Normal: No malignant cells present; compatible with benign diagnosis; supportive of conservative management; no evidence of endometrial cancer or atypical hyperplasia
- Positive/Abnormal: Presence of malignant cells; evidence of endometrial carcinoma, uterine sarcoma, or other malignancy; findings indicating atypical hyperplasia; suggests need for further surgical intervention
- Measurement Units: Tissue specimen size: 3-6 cm maximum dimension; histological findings reported in qualitative descriptive terms; grade and stage if malignancy is present
- Borderline/Equivocal Findings: Complex hyperplasia with or without atypia; cellular atypia of undetermined significance; findings requiring expert review or repeat biopsy; lesions suspicious but not diagnostic for malignancy
Interpretation
- Benign Diagnoses: Leiomyoma (uterine fibroids) - smooth muscle tumor with benign characteristics; Endometrial polyp - benign mucosal outgrowth; Adenomyosis - benign condition with ectopic endometrial tissue; Normal endometrial tissue; Indicates conservative management or expectant observation may be appropriate
- Malignant Diagnoses: Endometrial adenocarcinoma (Type I or Type II); Uterine sarcoma; Leiomyosarcoma; Carcinosarcoma; Requires urgent staging with imaging and surgical consultation; Determines need for hysterectomy and staging procedures
- Grade and Stage Information: Grade 1 (Low): Well-differentiated tumor, better prognosis; Grade 2 (Intermediate): Moderately differentiated, intermediate prognosis; Grade 3 (High): Poorly differentiated, worse prognosis; FIGO staging determines extent of disease and treatment recommendations
- Factors Affecting Results: Adequacy of tissue sample; location and depth of biopsy within lesion; presence of hormonal stimulation; patient age and menopausal status; concurrent medications (tamoxifen, hormone replacement); specimen handling and fixation quality; pathologist expertise and interpretation
- Clinical Significance: Definitive histological diagnosis guides treatment strategy; Benign results allow conservative management and symptom-based therapy; Malignant results necessitate comprehensive staging and oncological treatment planning; Results impact prognosis, survival rates, and follow-up surveillance protocols; Molecular testing may be recommended for certain malignancies (MSI, MMR status)
Associated Organs
- Primary Organ System: Uterus (corpus uteri); specifically the endometrium (inner lining) and myometrium (muscle layer); female reproductive system; associated structures include ovaries, fallopian tubes, and pelvic peritoneum
- Commonly Associated Benign Conditions: Uterine leiomyomas (fibroids); Endometrial polyps; Adenomyosis; Endometrial hyperplasia (simple or complex); Submucosal leiomyomas; Chronic endometritis
- Malignant Diseases Diagnosed: Endometrial adenocarcinoma (most common type of uterine cancer); Endometrial carcinoma Type I (estrogen-dependent); Endometrial carcinoma Type II (estrogen-independent, more aggressive); Uterine sarcomas including leiomyosarcoma; Carcinosarcoma (mixed Müllerian tumor); Endometrial stromal sarcoma
- Potential Complications of Abnormal Results: Metastatic spread to peritoneum, lymph nodes, or distant organs; Invasion into surrounding tissues and organs; Vaginal or vaginal vault recurrence; Pelvic inflammatory complications; Bowel or urinary tract obstruction from advanced disease; Psychological impact of cancer diagnosis; Loss of fertility if hysterectomy required in younger women
- Risk Factors for Malignancy: Postmenopausal status (especially unopposed estrogen); Tamoxifen therapy (breast cancer treatment); Obesity and metabolic syndrome; Diabetes mellitus; Hypertension; Family history of endometrial or ovarian cancer; Lynch syndrome (HNPCC); Nulliparity; Irregular menstrual cycles
Follow-up Tests
- If Benign Results: Pelvic ultrasound or MRI in 3-6 months to confirm stability of benign lesion; Hysteroscopy may be repeated if symptoms persist; Transvaginal ultrasound for ongoing surveillance; Symptom-directed imaging if bleeding recurs; No routine follow-up imaging if asymptomatic and benign diagnosis confirmed
- If Malignant Results: Complete staging imaging - CT or MRI pelvis and abdomen; Chest X-ray or CT chest to rule out pulmonary metastases; Laboratory studies: CBC, comprehensive metabolic panel, tumor markers (CA-125); Molecular testing: MSI/MMR status, Lynch syndrome screening if indicated; Surgical staging - total hysterectomy, bilateral salpingo-oophorectomy (TH-BSO); Pelvic and para-aortic lymph node assessment
- Molecular and Specialized Testing: POLE mutation analysis for endometrial cancer; p53 immunohistochemistry; ER/PR receptor status; HER2 status if indicated; PD-L1 expression; Lynch syndrome genetic counseling and testing (MLH1, MSH2, MSH6, PMS2); Genomic profiling for treatment guidance
- Monitoring Frequency for Malignancy: First 2 years post-treatment: Clinical evaluation every 3-4 months; Imaging at 3, 6, 9, and 12 months if high-risk features; Years 2-5: Clinical visits every 6 months; Surveillance imaging annually; After 5 years: Annual clinical surveillance indefinitely; More frequent monitoring if high-grade or advanced disease
- Related Complementary Tests: Transvaginal ultrasound for ongoing assessment; Hysteroscopy for direct visualization; Curettage specimen analysis if biopsy incomplete; Immunohistochemistry panels; Flow cytometry if sarcoma suspected; PET-CT for metastatic disease evaluation; Bone scan if indicated by symptoms
- If Equivocal/Borderline Results: Repeat biopsy with expanded sampling; Pathology review by gynecological pathology specialist; Immunohistochemistry for better characterization; Follow-up imaging in 4-6 weeks; Closer clinical surveillance and symptom monitoring; Consider endometrial ablation or hysterectomy based on clinical judgment
Fasting Required?
- Fasting Requirement: No - Fasting is NOT required for this biopsy procedure; This is a tissue sampling procedure, not a blood test
- Pre-procedure Instructions: Patient may eat and drink normally before procedure; Light meal 2-3 hours before appointment is acceptable; Standard NPO (nothing by mouth) applies only if general anesthesia planned; Local anesthesia typically does not require fasting
- Medications to Avoid: Anticoagulants (warfarin, apixaban) - hold 3-5 days before procedure unless high thromboembolic risk; Antiplatelet agents (aspirin) - hold 5-7 days before procedure; NSAIDs (ibuprofen, naproxen) - avoid 5-7 days before; Herbal supplements with anticoagulant properties (ginger, garlic, gingko) - hold 1 week prior; Discuss all medications with provider 1-2 weeks before procedure
- Other Patient Preparation Requirements: Obtain informed consent with explanation of procedure, risks, and benefits; Schedule during follicular phase of menstrual cycle if possible (days 5-12 of cycle); Empty bladder and bowel before procedure; Remove all metal objects and jewelry; Empty uterus preferable - not during menstruation; Pregnancy test if reproductive age and recent unprotected intercourse
- Infection Screening: Urine culture if signs of infection present; Rule out active pelvic infection; Screen for cervicitis or vaginitis; Treat infections before biopsy procedure
- Post-procedure Care Instructions: Mild cramping and spotting expected for several days; Avoid intercourse for 1-2 weeks; Avoid tampons for 1 week; Mild pain management with acetaminophen as needed; Avoid strenuous activity for 24-48 hours; Report fever, heavy bleeding, or severe pain; Prophylactic antibiotics may be given if indicated
- Contraindications and Precautions: Active pelvic infection or cervicitis - defer procedure; Pregnancy - contraindicated; Uncontrolled bleeding disorders; Severe cervical stenosis; Uncorrected coagulopathy; Recent uterine perforation or recent surgery; Severe cardiopulmonary disease may require modified approach

How our test process works!